Evidence map›Paper›PMID 22190036›Full record

ArticleNature2011

T-cell differentiation factor CBF-β regulates HIV-1 Vif-mediated evasion of host restriction.

Wenyan Zhang, Juan Du, Sean L Evans, Yunkai Yu, Xiao-Fang Yu

Abstract read
PubMed Publisher
In one paragraph

Article in Nature, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 192 papers.

0numbers the graph read from it
0cells of the map it votes in
192citing papers in PubMed
8.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

192 citing papers in PubMed, 256 citations in OpenAlex.

  1. Manipulation of the cell cycle by HIV-1.Biochemical Society transactions · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. HIV-1 Vif and Vpr cooperatively modulate the cell cycle to maximize per-cell virion production.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  8. Fitness Landscapes of APOBEC3G Antagonism by HIV-1 Vif proteins.bioRxiv : the preprint server for biology · 2025
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Current drug discovery technologies · 2025
    Article
  16. Structural insights into PPP2R5A degradation by HIV-1 Vif.Nature structural & molecular biology · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Review

132 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Wenyan ZhangFirst Hospital of Jilin University, Institute of Virology and AIDS Research, Changchun, Jilin Province 130021, China.
Juan Du
Sean L Evans
Yunkai Yu
Xiao-Fang Yu
Johns Hopkins University · USFirst Hospital of Jilin University · CN

Funding

Role of Cul5 E3 Ubiquitin ligasae in HIV Vif function: A novel regulatorR56AI062644 · NIAID · JOHNS HOPKINS UNIVERSITY · PI YU, XIAO-FANG · 2010 to 2010
$369k
Interaction between HIV-1 Vif and a Host Key Immune Regulator ComponentF31AI091326 · NIAID · JOHNS HOPKINS UNIVERSITY · PI EVANS, SEAN LAMONTE · 2011 to 2012
$84k
NIAID NIH HHS 2R56AI62644-6NIAID NIH HHS F31 AI091326
6 · The paper itself

Abstract

The human APOBEC3 cytidine deaminases are potent inhibitors of diverse retroviruses, including human immunodeficiency virus-1 (HIV-1). HIV-1 Vif forms an E3 ubiquitin ligase complex with cullin 5 (CUL5), elongin B and elongin C , which promotes the polyubiquitination and degradation of APOBEC3 substrates. Here we demonstrate in human T cells that core binding factor β (CBF-β) is a key regulator of the evasion of HIV-1 from the host defence mediated by APOBEC3. CBF-β, the non-DNA-binding subunit of a heterodimeric transcription factor, regulates the folding and DNA-binding activity of partner RUNX family proteins, which have important roles in the development and differentiation of diverse cell types, including T lymphocytes. In our study, knockdown of endogenous CBF-β blocked Vif-induced APOBEC3G polyubiquitination and degradation. CBF-β was not required for the interaction between Vif and APOBEC3G, yet was essential for the assembly of the Vif-CUL5 E3-ubiquitin-ligase complex. CBF-β proved to be a unique regulator of primate lentiviral Vif and not a general component of the CUL5 E3 ubiquitin ligase. We show that Vif and CBF-β physically interact, and that the amino-terminal region of Vif is required for this interaction. Furthermore, interactions with Vif required regions in CBF-β that are not involved in RUNX protein binding. Considering the importance of the interaction between Vif and CBF-β, disrupting this interaction represents an attractive pharmacological intervention against HIV-1.

Indexed as

Cell DifferentiationHost-Pathogen InteractionsImmune EvasionAPOBEC-3G DeaminaseCell LineCore Binding Factor alpha SubunitsCore Binding Factor beta SubunitCullin ProteinsCytidine DeaminaseGene Knockdown TechniquesHEK293 CellsHIV-1HumansImmunoprecipitationModels, MolecularProtein BindingAPOBEC-3G DeaminaseAPOBEC3G protein, humanCBFB protein, humanCore Binding Factor alpha SubunitsCore Binding Factor beta SubunitCUL5 protein, humanCullin ProteinsCytidine DeaminaseUbiquitin-Protein Ligasesvif Gene Products, Human Immunodeficiency Virus

Identifiers

PMID22190036
OpenAlexW2069676221

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.